SWOG S1007: Standard Adjuvant Chemotherapy in High-Risk Patients with Oncotype Recurrence Score of 25 or Less
A Phase III Randomized Trial of Standard Adjuvant Endrocrine THerapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor Positive and HER2/neu Negative Breast Cancer with Recurrence core (RS) of 25 or Less
Protocol Occurs in 2 Steps:
Step 1-Consent and Oncotype (Genomic Health genetic testing of multiple genetic factors of a patient's tumor). Genomic Health will attempt to negotiate with insurance company for testing. PATIENS WILL NOT BE CHARGED FOR ONCOTYPE TESTING.
Step 2-Randomiazation to treatment.
Specific Inclusion/Exclusion Criteria need to be met to be able to participate in this clinical trial.